HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals.
| Autor: | Rice DP Jr; Division of Infectious Diseases, Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA., Faragon JJ; Division of HIV Medicine, Albany Medical Center, Albany, NY, USA., Banks S; Department of Medicine, The Hospital of Central Connecticut, University of Connecticut School of Medicine, Farmington, CT, USA., Chirch LM; Division of Infectious Diseases, Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical and translational hepatology [J Clin Transl Hepatol] 2016 Sep 28; Vol. 4 (3), pp. 234-240. Date of Electronic Publication: 2016 Sep 25. |
| DOI: | 10.14218/JCTH.2016.00026 |
| Abstrakt: | Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade, resulting in better control of infection and clinical outcomes; however, drug-drug interactions remain a significant hazard. Joint recommendations from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America regarding drug-drug interactions between HIV antiretroviral agents and direct-acting antiviral agents for treatment of hepatitis C virus (HCV) infection are reviewed here. This review is oriented to facilitate appropriate selection of an antiviral therapy regimen for HCV infection based on the choice of antiretroviral therapy being administered and, if necessary, switching antiretroviral regimens. Competing Interests: Dr. Faragon has disclosed that he has received honoraria from AbbVie, BMS, Gilead, Merck, and Viiv. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|